Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Tuberculosis

  Free Subscription


26.03.2018

1 Chest
1 Eur Respir J
15 Int J Tuberc Lung Dis
1 J Clin Microbiol
2 J Infect Dis
1 Lancet Infect Dis
3 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Chest

  1. PROANO A, Bui D, Lopez JW, Vu NM, et al
    Cough Frequency During Treatment Associated with Baseline Cavitary Volume and Proximity to the Airway in Pulmonary Tuberculosis.
    Chest. 2018 Mar 17. pii: S0012-3692(18)30413-6. doi: 10.1016/j.chest.2018.
    PubMed     Text format     Abstract available


    Eur Respir J

  2. KIM CT, Kim TO, Shin HJ, Ko YC, et al
    Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


    Int J Tuberc Lung Dis

  3. COX V, Brigden G, Crespo RH, Lessem E, et al
    Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2018;22:407-412.
    PubMed     Text format     Abstract available

  4. YADAV R, Saini A, Kaur P, Behera D, et al
    Diagnostic accuracy of GenoType((R)) MTBDRsl VER 2.0 in detecting second-line drug resistance to M. tuberculosis.
    Int J Tuberc Lung Dis. 2018;22:419-424.
    PubMed     Text format     Abstract available

  5. HEYCKENDORF J, van Leth F, Avsar K, Glattki G, et al
    Treatment responses in multidrug-resistant tuberculosis in Germany.
    Int J Tuberc Lung Dis. 2018;22:399-406.
    PubMed     Text format     Abstract available

  6. SCHNIPPEL K, Firnhaber C, Berhanu R, Page-Shipp L, et al
    Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
    Int J Tuberc Lung Dis. 2018;22:393-398.
    PubMed     Text format     Abstract available

  7. HTET KKK, Soe KT, Kumar AMV, Saw S, et al
    Rifampicin-resistant tuberculosis patients in Myanmar in 2016: how many are lost on the path to treatment?
    Int J Tuberc Lung Dis. 2018;22:385-392.
    PubMed     Text format     Abstract available

  8. ONYOH EF, Kuaban C, Lin HH
    Pre-treatment loss to follow-up of pulmonary tuberculosis patients in two regions of Cameroon.
    Int J Tuberc Lung Dis. 2018;22:378-384.
    PubMed     Text format     Abstract available

  9. SHIN SS, Modongo C, Zetola NM, Wang Q, et al
    High rates of exposure to tuberculosis patients among HIV-infected health care workers in Botswana.
    Int J Tuberc Lung Dis. 2018;22:366-370.
    PubMed     Text format     Abstract available

  10. ADEPOYIBI T, Lilis L, Greb H, Boyle D, et al
    Which attributes within target product profiles for tuberculosis diagnostics are the most important to focus on?
    Int J Tuberc Lung Dis. 2018;22:425-428.
    PubMed     Text format     Abstract available

  11. MASKERY B, Posey DL, Coleman MS, Asis R, et al
    Economic analysis of CDC's culture- and smear-based tuberculosis instructions for Filipino immigrants.
    Int J Tuberc Lung Dis. 2018;22:429-436.
    PubMed     Text format     Abstract available

  12. HARRIES AD
    Impact of antiretroviral therapy on tuberculosis control.
    Int J Tuberc Lung Dis. 2018;22:466-467.
    PubMed     Text format    

  13. PAYEN MC, De Wit S
    In Reply: Synergy between amoxicillin and meropenem/clavulanate in drug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2018;22:465-466.
    PubMed     Text format    

  14. MISHRA GP, Caminero JA
    Low-dose amoxicillin-clavulanate in drug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2018;22:465.
    PubMed     Text format    

  15. CLICK ES, Ouma GS, DeGruy K, Murithi W, et al
    No evidence of Mycobacterium tuberculosis in breast milk of 18 women with confirmed TB disease in Kisumu, Kenya.
    Int J Tuberc Lung Dis. 2018;22:464-465.
    PubMed     Text format    

  16. MATHYS V, Roycroft E, Raftery P, Groenheit R, et al
    Time-and-motion tool for the assessment of working time in tuberculosis laboratories: a multicentre study.
    Int J Tuberc Lung Dis. 2018;22:444-451.
    PubMed     Text format     Abstract available

  17. BASHAM CA, Elias B, Fanning A, Cook C, et al
    Performance measurement of a Canadian provincial tuberculosis programme: Manitoba, 2008-2012.
    Int J Tuberc Lung Dis. 2018;22:437-443.
    PubMed     Text format     Abstract available


    J Clin Microbiol

  18. DAUM LT, Konstantynovska OS, Solodiankin OS, Liashenko OO, et al
    Next-Generation Sequencing for Characterizing Drug Resistant Mycobacterium tuberculosis Genes from Clinical Isolates in the Ukraine.
    J Clin Microbiol. 2018 Mar 21. pii: JCM.00009-18. doi: 10.1128/JCM.00009.
    PubMed     Text format     Abstract available


    J Infect Dis

  19. MURRAY LW, Satti I, Meyerowitz J, Jones M, et al
    Human Immunodeficiency Virus Infection Impairs Th1 and Th17 Mycobacterium tuberculosis-Specific T-Cell Responses.
    J Infect Dis. 2018 Mar 13. pii: 4932783. doi: 10.1093.
    PubMed     Text format     Abstract available

  20. URBANOWSKI ME, Ihms EA, Bigelow K, Kubler A, et al
    Repetitive Aerosol Exposure Promotes Cavitary Tuberculosis and Enables Screening for Targeted Inhibitors of Extensive Lung Destruction.
    J Infect Dis. 2018 Mar 15. pii: 4936447. doi: 10.1093.
    PubMed     Text format     Abstract available


    Lancet Infect Dis

  21. COX H, Hughes J, Black J, Nicol MP, et al
    Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?
    Lancet Infect Dis. 2018 Mar 13. pii: S1473-3099(18)30104.
    PubMed     Text format     Abstract available


    PLoS One

  22. WANGARI IM, Stone L
    Backward bifurcation and hysteresis in models of recurrent tuberculosis.
    PLoS One. 2018;13:e0194256.
    PubMed     Text format     Abstract available

  23. ESHETIE S, Gizachew M, Alebel A, van Soolingen D, et al
    Tuberculosis treatment outcomes in Ethiopia from 2003 to 2016, and impact of HIV co-infection and prior drug exposure: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0194675.
    PubMed     Text format     Abstract available

  24. ASHHURST AS, Parumasivam T, Chan JGY, Lin LCW, et al
    PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection.
    PLoS One. 2018;13:e0194620.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  25. ARREGUI S, Iglesias MJ, Samper S, Marinova D, et al
    Data-driven model for the assessment of Mycobacterium tuberculosis transmission in evolving demographic structures.
    Proc Natl Acad Sci U S A. 2018 Mar 21. pii: 1720606115.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: